Pail Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 19 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 7.00 M
- Revenue Growth -14.32%
- Profit Growth -45.55%
- Ebitda 8.55%
- Net Worth -0.06%
- Total Assets -0.72%
About Pail Pharma
Pail Pharma Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 February 2006 and has a history of 19 years. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company has closed loans amounting to ₹7.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pragya Gupta, Annu Rana, and Saroj Gupta serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232UP2006PTC031324
-
Company No.
031324
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Feb 2006
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Pail Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pragya Gupta
|
Director | 06-Feb-2006 | Current |
|
Annu Rana
|
Director | 06-Feb-2006 | Current |
|
Saroj Gupta
|
Director | 08-Jun-2024 | Current |
Financial Performance of Pail Pharma.
Pail Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 14.32% decrease. The company also saw a substantial fall in profitability, with a 45.55% decrease in profit. The company's net worth dipped by a decrease of 0.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pail Pharma?
In 2020, Pail Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹7.00 M
Charges Breakdown by Lending Institutions
- Icici Bank Limited : 0.50 Cr
- Punjab National Bank : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 May 2013 | Icici Bank Limited | ₹5.00 M | Satisfied |
| 05 May 2011 | Punjab National Bank | ₹2.00 M | Satisfied |
How Many Employees Work at Pail Pharma?
Unlock and access historical data on people associated with Pail Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pail Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pail Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.